Johnson & Johnson [JNJ] vs Gilead Sciences [GILD] Detailed Stock Comparison
Johnson & Johnson
NYSE
Loading...
Gilead Sciences
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Johnson & Johnson wins in 10 metrics, Gilead Sciences wins in 10 metrics, with 0 ties. Both stocks appear equally matched on key metrics.
View Metrics Details
Vital Metrics Comparison
| Metric | Johnson & Johnson | Gilead Sciences | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 19.04 | 22.73 | Johnson & Johnson |
| Price-to-Book Ratio | 5.46 | 7.23 | Johnson & Johnson |
| Debt-to-Equity Ratio | 64.69 | 127.34 | Johnson & Johnson |
| PEG Ratio | 1.06 | 1.05 | Gilead Sciences |
| EV/EBITDA | 15.23 | 11.66 | Gilead Sciences |
| Profit Margin (TTM) | 25.00% | 21.87% | Johnson & Johnson |
| Operating Margin (TTM) | 28.91% | 39.16% | Gilead Sciences |
| EBITDA Margin (TTM) | 28.91% | 39.16% | Gilead Sciences |
| Return on Equity | 30.21% | 33.40% | Gilead Sciences |
| Return on Assets (TTM) | 7.61% | 12.62% | Gilead Sciences |
| Free Cash Flow (TTM) | $18.06B | $10.31B | Johnson & Johnson |
| Dividend Yield | 2.47% | 3.25% | Gilead Sciences |
| 1-Year Return | 7.58% | 38.33% | Gilead Sciences |
| Price-to-Sales Ratio (TTM) | 4.73 | 4.92 | Johnson & Johnson |
| Enterprise Value | $460.71B | $160.94B | Johnson & Johnson |
| EV/Revenue Ratio | 5.08 | 5.58 | Johnson & Johnson |
| Gross Profit Margin (TTM) | 67.87% | 78.80% | Gilead Sciences |
| Revenue per Share (TTM) | $38 | $23 | Johnson & Johnson |
| Earnings per Share (Diluted) | $9.35 | $5.04 | Johnson & Johnson |
| Beta (Stock Volatility) | 0.39 | 0.38 | Gilead Sciences |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Johnson & Johnson vs Gilead Sciences Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Johnson & Johnson | -0.25% | -0.21% | 3.06% | 13.66% | 9.34% | 23.64% |
| Gilead Sciences | -2.81% | -0.43% | -4.56% | 2.23% | 0.49% | 24.67% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Johnson & Johnson | 7.58% | 6.24% | 19.36% | 90.66% | 189.20% | 173.18% |
| Gilead Sciences | 38.33% | 74.62% | 76.10% | 5.63% | 562.91% | 889.21% |
News Based Sentiment: Johnson & Johnson vs Gilead Sciences
Johnson & Johnson
News based Sentiment: POSITIVE
September was a positive month for Johnson & Johnson, driven by strong Q2 earnings, increased guidance, and continued investment in growth areas like biomanufacturing. While challenges remain, the overall narrative points to a resilient and well-positioned company, making it a favorable investment option.
Gilead Sciences
News based Sentiment: MIXED
Gilead reported strong Q2 results and is making significant investments in manufacturing and HIV prevention, signaling growth potential. However, continued insider selling and mixed analyst sentiment introduce uncertainty, creating a complex investment picture. The combination of positive financial performance and strategic initiatives alongside these concerns warrants a 'mixed' assessment.
Performance & Financial Health Analysis: Johnson & Johnson vs Gilead Sciences
| Metric | JNJ | GILD |
|---|---|---|
| Market Information | ||
| Market Cap | $428.83B | $142.13B |
| Market Cap Category | Mega cap | Large cap |
| 10 Day Avg. Volume | 7,498,410 | 6,749,120 |
| 90 Day Avg. Volume | 8,099,283 | 6,467,877 |
| Last Close | $178.06 | $114.55 |
| 52 Week Range | $140.68 - $181.16 | $81.57 - $121.83 |
| % from 52W High | -1.71% | -5.98% |
| All-Time High | $186.69 (Apr 25, 2022) | $123.37 (Jun 22, 2015) |
| % from All-Time High | -4.62% | -7.15% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.06% | 0.02% |
| Quarterly Earnings Growth | 0.18% | 0.21% |
| Financial Health | ||
| Profit Margin (TTM) | 0.25% | 0.22% |
| Operating Margin (TTM) | 0.29% | 0.39% |
| Return on Equity (TTM) | 0.30% | 0.33% |
| Debt to Equity (MRQ) | 64.69 | 127.34 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $32.61 | $15.84 |
| Cash per Share (MRQ) | $7.84 | $4.88 |
| Operating Cash Flow (TTM) | $23.03B | $9.87B |
| Levered Free Cash Flow (TTM) | $11.08B | $8.84B |
| Dividends | ||
| Last 12-Month Dividend Yield | 2.47% | 3.25% |
| Last 12-Month Dividend | $3.72 | $3.91 |
Valuation & Enterprise Metrics Analysis: Johnson & Johnson vs Gilead Sciences
| Metric | JNJ | GILD |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 19.04 | 22.73 |
| Forward P/E | 16.80 | 15.42 |
| PEG Ratio | 1.06 | 1.05 |
| Price to Sales (TTM) | 4.73 | 4.92 |
| Price to Book (MRQ) | 5.46 | 7.23 |
| Market Capitalization | ||
| Market Capitalization | $428.83B | $142.13B |
| Enterprise Value | $460.71B | $160.94B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 5.08 | 5.58 |
| Enterprise to EBITDA | 15.23 | 11.66 |
| Risk & Other Metrics | ||
| Beta | 0.39 | 0.38 |
| Book Value per Share (MRQ) | $32.61 | $15.84 |
Financial Statements Comparison: Johnson & Johnson vs Gilead Sciences
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | JNJ | GILD |
|---|---|---|
| Revenue/Sales | $21.89B | $6.67B |
| Cost of Goods Sold | $7.36B | $1.54B |
| Gross Profit | $14.54B | $5.13B |
| Research & Development | $3.23B | $1.38B |
| Operating Income (EBIT) | $6.30B | $2.49B |
| EBITDA | $8.72B | $3.28B |
| Pre-Tax Income | $13.63B | $1.65B |
| Income Tax | $2.63B | $334.00M |
| Net Income (Profit) | $11.00B | $1.32B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | JNJ | GILD |
|---|---|---|
| Cash & Equivalents | $38.47B | $7.93B |
| Total Current Assets | $71.55B | $16.90B |
| Total Current Liabilities | $56.90B | $12.34B |
| Long-Term Debt | $38.36B | $22.15B |
| Total Shareholders Equity | $78.11B | $19.08B |
| Retained Earnings | N/A | $10.93B |
| Property, Plant & Equipment | N/A | $7.96B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | JNJ | GILD |
|---|---|---|
| Operating Cash Flow | $6.35B | $1.56B |
| Capital Expenditures | $-795.00M | $-104.00M |
| Free Cash Flow | $3.37B | $1.65B |
| Debt Repayment | $-2.87B | $-1.76B |
| Common Stock Repurchase | $-2.13B | $-730.00M |
Short Interest & Institutional Ownership Analysis
| Metric | JNJ | GILD |
|---|---|---|
| Shares Short | 18.84M | 17.56M |
| Short Ratio | 2.26 | 2.79 |
| Short % of Float | 0.01% | 0.01% |
| Average Daily Volume (10 Day) | 7,498,410 | 6,749,120 |
| Average Daily Volume (90 Day) | 8,099,283 | 6,467,877 |
| Shares Outstanding | 2.41B | 1.25B |
| Float Shares | 2.40B | 1.24B |
| % Held by Insiders | 0.00% | 0.00% |
| % Held by Institutions | 0.74% | 0.91% |
Dividend Analysis & Yield Comparison: Johnson & Johnson vs Gilead Sciences
| Metric | JNJ | GILD |
|---|---|---|
| Last 12-Month Dividend | $3.72 | $3.91 |
| Last 12-Month Dividend Yield | 2.47% | 3.25% |
| 3-Year Avg Annual Dividend | $3.97 | $3.30 |
| 3-Year Avg Dividend Yield | 0.75% | 0.91% |
| 3-Year Total Dividends | $11.92 | $9.91 |
| Ex-Dividend Date | Feb 18, 2025 | Sep 15, 2025 |